Noninvasive Assessment of Liver Fibrosis in NAFLD

Sanyal, Arun J., Castera, Laurent, Wong, Vincent Wai-Sun·2023·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2023.03.042

Cited by (155)

Items 101–155 of 155

  1. Enhanced liver fibrosis test improves diagnostic efficiency and reduces testing costs for advanced liver fibrosis in steatotic liver disease
    Christel Pussinen, Anni Kelkka, Kari J. Pulkki, Anna Lempiäinen, Fredrik O. Åberg · 2025 · Scandinavian Journal of Gastroenterology
  2. Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarsin De Silva, H Janaka de Silva · 2025 · Expert Review of Gastroenterology & Hepatology
  3. CUN‑BAE predicts risk of metabolic dysfunction–associated steatotic liver disease: A prospective cohort study in non‑obese Chinese adults
    Xueyan Wu, Rong Zhang, Shenglian Gan, Haifeng Zhou, Fang Frank Yu, Jian Luo · 2025 · Scientific Reports
  4. Association between serum vitamin D levels and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study based on NHANES 2021–2023
    Shuo Zhou, You Xiao, Dengyong Zhang, Song Tao Yang, Yongliang Chen, Wanliang Sun · 2025 · Annals of Medicine and Surgery
  5. Dual elastography ultrasound for classifying metabolic dysfunction-associated steatotic liver disease: a cross-sectional study within a prospective cohort
    Sitong Chen, Yuejuan Gao, Guangwen Cheng, Fankun Meng, Ying Zheng, B. Zhang, Jie Chen, Yao Zhang, Zhiyong Yin, Hong Yang et al. · 2026 · Hepatology International
  6. Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina
    Bárbara Suarez, Adriana Mabel Álvarez, María Florencia Mascardi, A Ramos, Dong Hoon Woo, María Mercedes Gutiérrez, Guillermo Alzueta, María del Carmen Basbus, Santiago Bruzone, Patricia Cuart et al. · 2026 · Life
  7. Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults
    Kuan-Yu Lai, Ci Wang, Hsian-Han Kao, Wen‐Yuan Lin, Tsung‐Po Chen · 2026 · Metabolism Open
  8. Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
    K.N. Lai, Vincent Wai‐Sun Wong · 2026 · Singapore Medical Journal
  9. Bacteroides thetaiotaomicron and Bacteroides ovatus for the treatment of MAFLD: A comparative study of individual and combined effects
    Xiuxia Li, Guangpeng Zhou, Changrui Sun, Ruijing She, Wentao Feng, Xiliang Fu, Shuang Wu, Donghui Li, Lingai Pan, Xingchao Liu et al. · 2026 · The Journal of Nutritional Biochemistry
  10. Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?
    Patricia Casarolli Valery, Elizabeth Ellen Powell · 2023 · The Lancet. Gastroenterology & hepatology
  11. Mistakes in utilising histopathology for the management of liver disease
    Madunil Anuk Niriella, Dharani Kanagarajah, J. Hewavisenthi, H Janka de Silva · 2024 · Expert Review of Gastroenterology & Hepatology
  12. Challenges in the management of alcohol-associated liver disease in Latin America
    Francisco Javier Idalsoaga, Luis Antonio Díaz, Gustavo Ayares, Marco A. Arrese, Juan Pablo Arab · 2024 · Annals of Hepatology
  13. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Thierry Poynard, Olivier Deckmyn, Raluca Pais, Judith Aron‐Wisnewsky, Valentina Peta, Pierre Bédossa, Frédéric Charlotte, Maharajah Ponnaiah, Jean‐Michel Siksik, Jean-Michel Siksik et al. · 2025 · Diagnostics
  14. Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—The MAFLD fibrosis score
    Suzanne R. Sharpton · 2023 · Alimentary Pharmacology & Therapeutics
  15. Fibrosis status, extra-hepatic multimorbidity and all-cause mortality in 53093 women and 74377 men with MASLD in UK Biobank
    Qi Feng, Chioma N. Izzi‐Engbeaya, Pinelopi Manousou, Mark Woodward · 2025 · medRxiv
  16. Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—the MAFLD fibrosis score. Authors' reply
    Johnny T. K. Cheung, Wah‐Kheong Chan, Ming‐Hua Zheng, Vincent Wai‐Sun Wong · 2023 · Alimentary Pharmacology & Therapeutics
  17. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
    Edilmar Alvarado‐Tápias, Douglas Maya‐Miles, Agustı́n Albillos, R. Aller, Javier Ampuero, Raúl J. Andrade, María Arechederra, Patricia Aspichueta, Jesús M. Bañales, Ana Blas‐García et al. · 2024 · Gastroenterología y Hepatología
  18. RETRACTED
    Yimin Wu, Lifang Fan, Jiang Cheng, Daojing Xu, Kun Wang, Ziyang Dou, Pingyang Zhang, Junli Wang · 2024 · Research Square
  19. Genome-wide insights into the shared genetic landscape between metabolic dysfunction-associated fatty liver disease and cardiovascular diseases
    Jun Qiao, Miaoran Chen, Minjing Chang, Wenjia Xie, Wenqi Ma, Tongtong Yang, Qianru Zhao, Kaixin Yao, Xichen Yang, Quan Yun et al. · 2024 · medRxiv
  20. Quantitative pharmacodynamics functional evaluation of Chinese medicine Qizhu formula in mice with dynamic near-infrared photoacoustic imaging
    Qingjuan Wu, Lan-Yu Chen, Quan-Mei Sun, Ning Wang, Dong Han, Wenliang Lv · 2024 · Photoacoustics
  21. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
    Edilmar Alvarado‐Tápias, Douglas Maya‐Miles, Agustı́n Albillos, R. Aller, Javier Ampuero, Raúl J. Andrade, María Arechederra, Patricia Aspichueta, Jesús M. Bañales, Ana Blas‐García et al. · 2024 · Gastroenterología y Hepatología (English Edition)
  22. Approche de la stéatose hépatique en clinique
    Andrew Szilagyi, Nir Hilzenrat · 2025 · Canadian Family Physician
  23. Approach to steatotic liver disease in the office
    Andrew Szilagyi, Nir Hilzenrat · 2025 · Canadian Family Physician
  24. Non-invasive Assessment of Advanced Fibrosis and Steatosis in Chronic Hepatitis B Patients with Comorbid NAFLD
    Zhenhua Zhou, Feng Chen, Rongrong Zou, Qianhui Li, Xiaomin Xu · 2025 · Hepatitis Monthly
  25. The Role of Clinical Chemistry in Early Detection of Liver Disorders
    Fawaz Fathel Abd, Zainab Abdul Hassan Jabar, Afrah Jalal Abd Al Kadhim, Shaiban Mohammed Hussein, Zahra Osama Abbas · 2025 · Bright Sky Publications eBooks
  26. Diagnostic accuracy of predictive indices for assessing liver steatosis and fibrosis as compared to transient elastography in patients with non-alcoholic fatty liver disease
    R. M. Brekhunets, Д. Н. Андреев, Igor Veniaminovich Maev, Diana T. Dicheva, Кулиева Алла Киримовна · 2025 · Meditsinskiy sovet = Medical Council
  27. A Multi-Modal Deep Fusion Network: Enhancing Graft Survival Prediction in Non-Alcoholic Fatty Liver Disease Patients Prior to Liver Transplantation
    Devi Rajeev, S Remya, Anand Nayyar · 2025 · IEEE Multimedia
  28. Current and Investigational Biomarkers of Liver Disease in HIV-HBV Co-infection
    Keyur Patel, Giada Sebastiani · 2025 · Current HIV/AIDS Reports
  29. Preparation of high-affinity monoclonal antibodies against the liver fibrosis biomarker CHI3L1 and development of detection methods
    Chen Duan, Zijian Zhou, Junxi Liu, Nami Liao, Xu Ye, X Y Zhang, Rui Wang, Xiangjun Ai, Defu Hou, Qinglin Wang et al. · 2025 · Microchemical Journal
  30. Modern aspects of management of patients with metabolic dysfunction-associated steatotic liver disease
    Vladislav Vladimirovich Tsukanov, Alexander Viktorovich Vasyutin, Yu.L. Tonkikh · 2025 · Meditsinskiy sovet = Medical Council
  31. Avaliação do risco de fibrose hepática no pré-operatório da cirurgia bariátrica através do Fibrose-4 score (FIB 4): Análise observacional retrospectivo
    José Daniel Mera Rivas, Cindy Estephania Franco Cedeño, Nathali Bencosme, Juan Miguel Macharé Torres, Frederico Japiassu Santiago, Gabrielle Vaz de Azevedo David, Guilherme Lemos Cotta Pereira · 2025 · Research Society and Development
  32. Efficacy of pangenotypic direct‐acting antivirals in treating hepatitis C virus infection: A comparative analysis of urban and rural settings
    Hsing‐Jung Yeh, Kuan‐Chieh Fang, Yu‐Ching Weng, Jau‐Min Lien, Chun‐Chao Chang, Wei‐Yu Kao · 2025 · Advances in digestive medicine
  33. Collagen IV-targeted phase-change nanoparticles illuminate early liver fibrosis staging via ultrasound molecular imaging.
    Y. Long, Shigeng Zhong, Fang Li, Wei Zhang, Ya-Qin Hu, Mingyuan Dai, Min Zheng, Long Cheng, Hai-Tao Ran · 2025 · Biomaterials Science
  34. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort
    Thierry Poynard, Olivier Deckmyn, Valentina Peta, Raluca Pais, Bernard E. VAN BEERS, Laurent Castéra, Frédéric Charlotte, Valérie Paradis, Pierre Bédossa, Dominique Charles Valla · 2025 · Biomedicines
  35. Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index
    Umut Bakay, Tuğba İzci Duran, Özge Sevil Karstarlı Bakay, Rahime Ekmekçioğlu · 2025 · Dermatology Practical & Conceptual
  36. Evaluation of Liver Fibrosis and Metabolic Risk in Non-Alcoholic Fatty Liver Disease
    Gagan Bansal, Vinayak Madhukar Jedhe, Mohamad Akram · 2026 · Journal of Pharmacy And Bioallied Sciences
  37. Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
    Saeed Khavari Khorasani, Siavash Boroumandi, Ali Darzi, Mahla Shokouhfar, Pedram Abdali, Pooya Eini, Ahmad Ghorbani Vanan, Nastaran Bahrami · 2026 · Clinical and Experimental Medicine
  38. Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy
    Shirley Huey Shin Bong, Kevin Kim‐Jun Teh, Vincent Wai‐Sun Wong · 2026 · Clinical and Molecular Hepatology
  39. Refining HEPAmet for Treatment Eligibility in Metabolic Dysfunction-Associated Steatotic Liver Disease: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease
    Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Hideki Hayashi, Hirokazu Takahashi, Mary Eugenia Rinella, Yoshihiro Kamada, Yoshio Sumida, Miwa Kawanaka, Michihiro Iwaki et al. · 2026 · Clinical Gastroenterology and Hepatology
  40. Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD
    Hancheng Yu, Yumei Huang, Jingyao Wang, Jijuan Zhang, Ling Yang, Tingting Geng, Gang Liu, Pan A, Yunfei Liao · 2026 · Diabetes Obesity and Metabolism
  41. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review
    Zalina Yuryevna Sozaeva, М. В. Атаева, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, A G Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Yulia Nikolaevna Sharaf · 2026 · Journal Of Biochemical Technology
  42. Hepatic steatosis: A pandemic disease causing serious secondary diseases
    Ali Canbay, Anja Figge, Polykarpos Patsalis, Theodor Baars, Mustafa Kemal Özcürümez, Oliver Götze · 2026 · Deutsches Ärzteblatt international
  43. AI/ML-enabled biosensing platforms for MASLD and MASH: Biomarkers, modalities, and translational readiness
    Parkhi Disha, R Harikrishnan, Sampada Tavse, P. Srideviponmalar · 2026 · Biosensors and Bioelectronics X
  44. Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies
    Sukwoo Han, Jaehee Shin, Jae Cheon Kim, Dong Hee Na · 2026 · Journal of Pharmaceutical Investigation
  45. Metabolic dysfunction–associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver
    Mohit Kehar, Alnoor S. Ramji, Mark Swain, Alexander G. Singer, NOAH IVERS, Wendy Schaufert, Michael Betel, Kaberi Dasgupta, Giada Sebastiani, Keyur Patel · 2026 · Canadian Liver Journal
  46. Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
    Zobair M. Younossi, George Papatheodoridis, Emmanuel A. Tsochatzis, Marı́a Buti, Lorenza Rimassa, Massimo Pinzani, Ana Lleò, Debbie Lindsay Shawcross, Frank Tacke, Vincent Wai‐Sun Wong et al. · 2026 · Liver International
  47. The utility of emerging fibrosis scoring systems in MASLD: A paradigm shift toward non-invasive, multimodal risk stratification beyond histology
    Thomas Karlas, Eva Katharina Messer, Johannes Wiegand · 2026 · Zeitschrift für Gastroenterologie
  48. Analytical Validation and Preliminary Clinical Evaluation of Plasma Carboxylesterase 1 for Ultrasound-Defined Hepatic Steatosis
    Makito Tanaka, Shingo Tanaka, Kayoko Ochi, Ryo Kobayashi, Ryosei Murai, Satoshi Takahashi · 2026 · Diagnostics
  49. Diagnostic performance of FIB-6 for identifying FibroScan-defined advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a cross-sectional diagnostic accuracy study
    Hossein Bagheri, Niloofar Seighali, Mohammad Sadra Gholami Chahkand, Mahmood Bakhtiyari, Fateme Seighali, Fatemeh Jodeiri, Mohsen Rajabnia · 2026 · BMC Gastroenterology
  50. Metabolic dysfunction-associated steatotic liver disease in primary care: an international Delphi consensus
    Gong Feng, 宫守平, Frank Tacke, Luca V. C. Valenti, Mark Dhinesh Muthiah, Koki Kato, Zhaoxiang Yu, Giovanni Targher, Christopher D. Byrne, Mohamed Farouk Allam et al. · 2026 · The Lancet Primary Care
  51. Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH
    Rohit Seth Loomba, Ruiqiu Chen, Youxin Wang, Ricki Bettencourt, Egbert V. Madamba, Kaleb Tesfai, Lisa Richards, Mark Dhinesh Muthiah, Eunice Tan, Dan Yock Young et al. · 2026 · Hepatology
  52. EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy
    Frank Tacke, Paul Horn, Vincent Wai Sun Wong, Vlad Ratziu, Elisabetta Bugianesi, Sven Francque, Shira Zelber‐Sagi, Cyrielle Caussy, Michael Roden, Amalia Gastaldelli et al. · 2026 · Journal of Hepatology
  53. Prevalence of non-alcoholic fatty liver disease across populations and comorbid conditions: An umbrella review of meta-analyses
    Yue Feng, Peiye Wu, Rui Zhao, Xiaoding Shen, Xixuan Peng, Leyao Qiu, Can Zhu, Zhuolin Jiang, Huatian Gan, Qianyi Wan · 2026 · Therapeutic Advances in Gastroenterology
  54. Changes in the FIB-4 index with IL-23 vs IL-17 inhibitors in psoriasis: a retrospective cohort study
    Gözde Ulutaş Demirbaş, Abdullah Demirbaş, Esin Diremsizoğlu · 2026 · Expert Opinion on Biological Therapy
  55. Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity
    Pin‐Nan Cheng, Chia‐Wen Lu, Chih Lin Lin, Chien‐Hsieh Chiang, Hwai‐I Yang, Hsiang‐Han Kao, Chia‐Chi Wang, Tzu-Jung Chou, Ming‐Ling Chang, Tun-Jen Hsiao et al. · 2026 · Liver International